Perpetual Ltd Sells 80,864 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

Perpetual Ltd reduced its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 2.2% in the first quarter, HoldingsChannel reports. The institutional investor owned 3,551,813 shares of the biotechnology company’s stock after selling 80,864 shares during the quarter. Perpetual Ltd’s holdings in ADMA Biologics were worth $70,468,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of ADMA. B Group Inc. purchased a new stake in shares of ADMA Biologics in the fourth quarter valued at about $39,231,000. Raymond James Financial Inc. purchased a new stake in ADMA Biologics in the 4th quarter valued at about $19,076,000. Arrowstreet Capital Limited Partnership increased its stake in ADMA Biologics by 57.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 2,762,700 shares of the biotechnology company’s stock valued at $47,380,000 after buying an additional 1,013,456 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of ADMA Biologics by 16.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company’s stock worth $80,065,000 after buying an additional 643,661 shares in the last quarter. Finally, Man Group plc boosted its stake in shares of ADMA Biologics by 305.5% in the 4th quarter. Man Group plc now owns 745,300 shares of the biotechnology company’s stock worth $12,782,000 after buying an additional 561,507 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ADMA has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th. Raymond James Financial raised their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a research report on Thursday, May 8th. Finally, Wall Street Zen cut ADMA Biologics from a “hold” rating to a “sell” rating in a research note on Friday, May 9th.

Insider Buying and Selling at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 7,779 shares of ADMA Biologics stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $20.32, for a total value of $158,069.28. Following the completion of the transaction, the director now owns 114,830 shares in the company, valued at $2,333,345.60. This trade represents a 6.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jerrold B. Grossman sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the sale, the director now directly owns 478,194 shares in the company, valued at approximately $10,190,314.14. This trade represents a 2.05% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 464,621 shares of company stock worth $9,644,269 over the last ninety days. 3.50% of the stock is currently owned by company insiders.

ADMA Biologics Stock Up 4.5%

ADMA Biologics stock opened at $18.40 on Friday. The firm has a 50 day moving average price of $20.69 and a 200-day moving average price of $18.76. The company has a quick ratio of 3.36, a current ratio of 6.58 and a debt-to-equity ratio of 0.22. ADMA Biologics Inc has a twelve month low of $10.21 and a twelve month high of $25.67. The company has a market capitalization of $4.39 billion, a P/E ratio of 21.65 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The firm had revenue of $114.80 million during the quarter, compared to analysts’ expectations of $116.40 million. During the same quarter in the previous year, the company posted $0.08 EPS. ADMA Biologics’s revenue for the quarter was up 40.2% on a year-over-year basis. As a group, equities analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.